Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Organon Pays $12 Million for Assisted Reproduction Candidate

publication date: Sep 17, 2024

Organon China, a women’s health company, acquired China rights to an ovarian stimulation therapy from Shanghai Bao Pharmaceuticals. SJ02 was developed for patients in assisted reproductive programs. The candidate is a long-acting product designed to develop multiple follicles for one week after a single dose, while the current standard of care requires daily shots for a week. Bao has filed a BLA with China regulators for SJ02. If approved, the candidate will be the first long-acting ovarian stimulation product in China. Organon will pay $12 million upfront for the rights plus unspecified milestone payments. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here